证券代码：688314 证券简称：康拓医疗 公告编号：2023-010 西安康拓医疗技术股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 03 月 31 日(星期五) 下午 14:00-15:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 24 日(星期五)至 03 月 30 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2023 年 3 月 24 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年 年度经营成果、财务状 ...

证券代码：688314 证券简称：康拓医疗 编号：2022-004 西安康拓医疗技术股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | □√特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | | □√现场参观 □其他(请文字说明 ) | | | 2022 年 5 月 11 日 | 14:00-16:00 | | | 陕西金资基金 | ...

证券代码：688314 证券简称：康拓医疗 编号：2022-003 西安康拓医疗技术股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|-----------------------------------------------|-------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 | □√业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | | □现场参观 □其他(请文字说明 ) | | 参与单位 | 2022 年度业绩说明会 | 年陕西辖区上市公司投资者集体接待日暨 2021 | | 时间 | 2022 年 5 月 13 日 | 15:00-17:00 | | 地点 | 全景路演 | | | 公司参会人员姓名 | 董事长胡立人先生 董事会秘书、财务总监吴优女士 | | | | PEEK | 问题一、胡董您好！想请问一下贵公司 3D ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥63,085,811.80, representing a year-over-year increase of 14.10%[5] - Net profit attributable to shareholders decreased by 5.22% to ¥25,756,165.37 for the quarter, while the net profit excluding non-recurring gains and losses was ¥22,145,987.73, down 2.01%[5] - The basic earnings per share for the quarter were ¥0.44, a decrease of 6.38% compared to the same period last year[6] - The weighted average return on equity was 4.97%, down 0.81 percentage points year-over-year[6] - The total comprehensive income attributable to the parent company for Q3 2022 was CNY 66,646,445.75, compared to CNY 61,961,081.14 in Q3 2021, reflecting an increase of approximately 7.3%[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥623,455,920.67, an increase of 8.73% compared to the end of the previous year[6] - Total liabilities increased to ¥91,969,716.34 in the third quarter of 2022 from ¥71,984,609.68 in the same quarter of 2021, representing a rise of approximately 27.7%[21] - The total equity attributable to shareholders increased by 5.83% to ¥532,670,720.64 compared to the end of the previous year[6] - The total equity attributable to shareholders increased to ¥532,670,720.64 from ¥503,322,688.90, representing a growth of about 5.8%[21] Cash Flow - Cash flow from operating activities for the year-to-date was ¥74,932,246.33, reflecting a growth of 9.98%[6] - The net cash flow from operating activities for the first nine months of 2022 was CNY 74,932,246.33, up from CNY 68,132,297.09 in the same period of 2021, indicating a growth of about 12.9%[29] - The cash inflow from operating activities totaled CNY 210,741,748.56 in Q3 2022, compared to CNY 188,256,785.37 in Q3 2021, representing an increase of approximately 11.9%[29] - The company's cash and cash equivalents increased to ¥395,643,085.22 in the third quarter of 2022, up from ¥375,769,177.70 in the previous quarter, showing a growth of about 5.1%[20] - The cash and cash equivalents at the end of Q3 2022 amounted to CNY 250,652,931.07, compared to CNY 158,674,455.57 at the end of Q3 2021, showing an increase of about 57.8%[30] Research and Development - Research and development (R&D) expenses for the quarter amounted to ¥5,113,614.39, a significant increase of 106.72% year-over-year, reflecting higher personnel costs and new product registration expenses[11] - R&D expenses accounted for 8.11% of operating revenue, up 3.64 percentage points from the previous year[6] - Research and development expenses for the first three quarters of 2022 were ¥11,122,398.10, compared to ¥8,228,680.85 in the same period of 2021, indicating an increase of approximately 35.5%[24] - The company invested significantly in R&D, particularly in promoting thoracic and dental products, which impacted net profit growth[16] Revenue Breakdown - The company achieved operating revenue of 178.48 million RMB for the year-to-date period, representing an 18.16% increase year-over-year[16] - Revenue from PEEK material cranial repair products reached 107.52 million RMB, up 21.68% compared to the same period last year[16] - The revenue from titanium material cranial repair products was 54.66 million RMB, marking a 5.20% increase year-over-year[16] - The revenue from PEEK material sternal fixation systems surged to 5.77 million RMB, a remarkable 80.63% increase year-over-year[16] Investment Activities - The net cash flow from investing activities for the first nine months of 2022 was -CNY 114,685,668.05, an improvement from -CNY 185,909,376.41 in the same period of 2021[30] - The total cash inflow from investment activities in Q3 2022 was CNY 528,263,335.50, significantly higher than CNY 238,801,341.14 in Q3 2021, marking an increase of about 108.3%[29] - The total cash outflow from investment activities in Q3 2022 was CNY 642,949,003.55, compared to CNY 424,710,717.55 in Q3 2021, reflecting an increase of approximately 51.5%[30] - The company received CNY 526,000,000.00 from other investment-related cash activities in Q3 2022, compared to CNY 238,000,000.00 in Q3 2021, indicating a growth of about 105.8%[29] Inventory and Accounts Payable - The company’s inventory stood at approximately 38.62 million RMB as of September 30, 2022[18] - The company reported a decrease in accounts payable from ¥15,026,911.27 in the previous quarter to ¥10,666,174.28 in the current quarter, a reduction of about 29.5%[20] - Deferred income tax assets decreased to ¥2,890,438.58 from ¥3,161,943.61, reflecting a decline of approximately 8.5%[20]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a year-over-year growth of 15%[1]. - The company's operating revenue for the first half of 2022 was ¥115,394,434.94, representing a year-on-year increase of 20.50% compared to ¥95,765,463.55 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was ¥39,142,549.54, an increase of 12.71% from ¥34,728,250.67 in the previous year[19]. - The net cash flow from operating activities increased by 52.33% to ¥46,632,408.23, compared to ¥30,612,806.46 in the same period last year[22]. - The company achieved a main business revenue of 110.15 million yuan, an increase of 19.02% compared to the same period last year[32]. - The company reported revenue of 4.41 million yuan for its thoracic surgery product, PEEK sternum fixation belt, during the reporting period, reflecting a growth of 183.63% year-on-year[42]. - The company’s PEEK material neurosurgical products generated revenue of 67.62 million yuan, a growth of 23.99% year-on-year, accounting for 61.39% of the main business revenue[64]. - The company’s titanium material neurosurgical products generated revenue of 36.17 million yuan, reflecting a year-on-year growth of 5.90%[64]. Market Expansion and Product Development - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 10% to 15% based on current market trends[1]. - New product development includes the launch of a next-generation titanium cranial repair product, expected to enhance market competitiveness and drive sales growth[1]. - The company is expanding its market presence, targeting new regions in Asia, with plans to enter three additional countries by the end of 2022[1]. - A strategic acquisition of a smaller medical device firm is in progress, aimed at enhancing the company's product portfolio and technological capabilities[1]. - The company is expanding its product lines in neurosurgery and thoracic surgery, with plans to extend into oral and spinal fields[32]. - The company is pursuing registration for its PEEK cranial repair and fixation products in international markets, including the United States, Mexico, Brazil, and Argentina, to expand its business[44]. Research and Development - The company has allocated 100 million RMB for research and development in innovative medical technologies over the next year[1]. - The R&D expenditure as a percentage of operating revenue was 5.21%, a decrease of 0.8 percentage points from 6.01% in the previous year[21]. - R&D expenses totaled CNY 6,008,783.71, an increase of 4.41% from CNY 5,755,013.65 in the same period last year, with R&D expenses accounting for 5.21% of total revenue[51]. - The company has applied for a total of 3 new patents during the reporting period, bringing the cumulative total to 47 applications and 40 granted patents[50]. - The company has completed product process validation, design verification, and clinical evaluation for the bio-regenerative material artificial dura mater, with plans to submit an FDA certification application in the second half of the year[49]. Risk Management - The company has identified potential risks related to supply chain disruptions but has implemented strategies to mitigate these risks[1]. - The company faces risks related to new product development failures, market demand changes, and core technology protection, which could adversely affect its long-term competitiveness[74]. - The company is exposed to risks associated with maintaining stable relationships with distributors, which are crucial for sales performance[81]. - The company faces risks related to the implementation of centralized procurement policies, which could significantly impact sales and pricing if products are included in such policies[78]. Shareholder and Governance - The company has commitments from major shareholders and executives regarding share lock-up periods, with specific durations of 12 to 36 months post-IPO[111]. - The company will not transfer or entrust others to manage shares held before the IPO for 36 months from the date of the IPO[116]. - The company’s controlling shareholder has pledged not to interfere with the company's management or infringe on its interests, and will bear compensation responsibilities for any violations[136]. - The company will ensure timely and truthful reporting of shareholding changes by its directors and senior management[121]. - The company has established a share lock-up commitment for core technical personnel, restricting share transfers to no more than 25% of their total holdings annually after the lock-up period[112]. Financial Position - The company's total assets as of June 30, 2022, were ¥597,186,925.13, reflecting a 4.15% increase from ¥573,379,179.06 at the end of the previous year[20]. - The total liabilities increased from ¥61,502,269.25 to ¥83,152,085.46, marking a rise of about 35.2%[195]. - The company's cash and cash equivalents decreased by 34.97% to ¥211,560,715.95, down from ¥325,333,432.06 in the previous year[90]. - The company has made significant investments in long-term equity, with long-term equity investments rising to CNY 84,635,526.88 from CNY 48,239,026.88, an increase of about 75.5%[198].

Financial Performance - Revenue for Q1 2022 reached ¥53,501,448.21, an increase of 30.15% compared to the same period last year[5] - Net profit attributable to shareholders was ¥18,031,944.39, reflecting a growth of 29.25% year-over-year[5] - Net profit excluding non-recurring gains and losses increased by 63.68% to ¥17,721,527.77[5] - Basic earnings per share for the period was ¥0.31, a decrease of 3.13% compared to the previous year[6] - The company achieved a main business revenue of 53.50 million RMB, a year-on-year increase of 30.15%[15] - Operating profit for Q1 2022 was ¥21,243,683.61, up 31.5% from ¥16,128,936.29 in the same period last year[23] - Net profit for Q1 2022 was ¥17,578,386.38, representing a 28.5% increase compared to ¥13,735,757.86 in Q1 2021[24] Cash Flow - Net cash flow from operating activities was ¥15,656,175.96, up 113.71% year-over-year[5] - The increase in operating cash flow was attributed to higher sales revenue and stable cash outflows compared to the previous year[10] - Cash flow from operating activities increased to ¥15,656,175.96 in Q1 2022, compared to ¥7,325,746.34 in Q1 2021, marking a 114.8% rise[26] - The company reported a net cash increase of ¥183,439,754.46 at the end of Q1 2022, down from ¥71,642,038.21 at the end of Q1 2021[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥600,780,145.86, representing a 4.78% increase from the end of the previous year[6] - Total assets as of March 31, 2022, amounted to 600.78 million RMB, compared to 573.38 million RMB at the end of 2021[20] - Total liabilities increased to 81.89 million RMB from 71.98 million RMB year-on-year[20] - The equity attributable to shareholders reached 521.27 million RMB, up from 503.32 million RMB at the end of 2021[20] Research and Development - R&D investment totaled ¥2,481,241.25, down 39.27% compared to the previous year[6] - R&D expenditure as a percentage of revenue was 4.64%, a decrease of 5.30 percentage points year-over-year[6] - Research and development expenses decreased to ¥2,481,241.25 in Q1 2022 from ¥4,085,590.97 in Q1 2021, a reduction of 39.3%[23] - The company’s research project "3D printed PEEK cranial system" received approval for special review, expediting its market entry[16] Revenue Breakdown - Revenue from PEEK material cranial repair fixation products was 31.47 million RMB, growing by 30.43% year-on-year[15] - Revenue from titanium material cranial repair fixation products was 15.90 million RMB, with an 8.73% year-on-year increase[15] - The PEEK material sternum fixation system generated revenue of 2.07 million RMB, a significant increase of 514.11% year-on-year[15] Other Financial Metrics - Total operating costs for Q1 2022 were ¥31,854,707.27, an increase of 18.2% from ¥26,951,005.33 in Q1 2021[23] - The company experienced a decrease in other comprehensive income, reporting a net loss of ¥86,782.24 in Q1 2022 compared to a gain of ¥449,491.56 in Q1 2021[24] - Cash flow from investing activities showed a net outflow of ¥170,936,303.22 in Q1 2022, worsening from a net outflow of ¥27,985,345.84 in Q1 2021[26] Market Activities - The company increased its market promotion efforts, contributing to the rise in revenue[9] - The company completed a 16.67% equity investment in BPA, facilitating the introduction of a wireless intracranial pressure monitor[16]

Financial Performance - The company reported a total revenue of 5,600 million RMB for the year, with a significant increase from 3,016.04 million RMB in the previous year, representing a growth of approximately 86%[71]. - The company's operating revenue for the reporting period was approximately ¥212.55 million, representing a year-on-year increase of 29.54%[92]. - The net profit attributable to shareholders of the listed company rose by 55.83% year-on-year to approximately ¥81.63 million, while the net profit after deducting non-recurring gains and losses increased by 46.34% to approximately ¥66.40 million[21]. - The company's total assets at the end of 2021 were approximately ¥573.38 million, reflecting a 96.70% increase compared to the end of 2020[21]. - The net cash flow from operating activities increased by 78.61% year-on-year, amounting to approximately ¥103.29 million, attributed to the increase in product revenue during the reporting period[23]. - The company's financial expenses decreased significantly by 82.08% due to increased interest income from public offering proceeds[92]. - The company reported a net profit margin of 490.43 million, indicating strong profitability[140]. - The company achieved a total R&D expenditure of ¥16,804,775.34, a decrease of 0.56% compared to the previous year[66]. Dividend and Share Capital - The company plans to distribute a cash dividend of 6.20 RMB per 10 shares, totaling approximately 35.98 million RMB, which represents 44.08% of the net profit attributable to shareholders for 2021[7]. - The total share capital of the company as of the end of the reporting period was 58,027,980 shares[7]. - The company distributed a cash dividend of 0.52 CNY per share, totaling 30,174,549.60 CNY, based on a total share capital of 58,027,980 shares[160]. Corporate Governance - The company has received a standard unqualified audit opinion from its accounting firm[8]. - There are no special arrangements for corporate governance applicable to the company[9]. - The company has confirmed that all board members attended the board meeting[6]. - The company has established internal management systems for subsidiaries, including financial management and internal auditing, to ensure stable operations[163]. - The company emphasizes ESG principles, focusing on product quality, cost reduction, and governance improvements to enhance shareholder value and sustainable development[165]. - The company maintains a transparent governance structure, ensuring compliance with legal requirements and protecting the interests of shareholders and creditors[173]. Market and Product Development - The company plans to continue expanding its market presence and enhancing product offerings, particularly in the neurosurgical sector[23]. - The company is focused on expanding its product lines in neurosurgery and thoracic surgery, while also extending into oral and spinal fields[38]. - The company is actively developing new products, including artificial dura mater and disposable neurosurgical drainage devices, to expand its product line in the cranial repair segment[56]. - The company has established cooperation with over 300 distributors, covering 1,500 hospitals, including 900 tertiary hospitals[33]. - The company is developing a 3D printed PEEK craniofacial system using laser sintering technology, which improves processing efficiency and reduces material waste[55]. Research and Development - The research and development expenditure as a percentage of operating revenue was 7.91%, a decrease of 2.39 percentage points from 10.30% in 2020[23]. - The company has received 7 new patent authorizations during the reporting period, including 3 invention patents and 4 utility model patents, bringing the total to 7 invention patents and 14 utility model patents[36]. - The company has established a dedicated team for intellectual property management, conducting patent searches during new product development to avoid redundant research and investment[184]. - The company has improved the injection molding process for PEEK materials, enhancing production efficiency and reducing material waste[63]. Risks and Challenges - The company faces risks related to new product development and registration failures, which could adversely affect long-term core competitiveness[77]. - There is a risk of supply chain disruption for critical raw materials, particularly PEEK and titanium, which could impact production and sales if suppliers fail to meet quality standards or increase prices[79]. - The company is exposed to risks from centralized procurement policies for high-value medical consumables, which could lead to significant price reductions and impact sales[82]. - The integration of the subsidiary BIOPLATE poses management challenges, and failure to effectively manage this integration could affect profitability[80]. Employee and Management - The company has expanded its workforce by adding 31 new employees, including 8 in R&D and 10 in sales, to strengthen its talent pool[36]. - The number of R&D personnel increased to 41, accounting for 20% of the total workforce, up from 19% in the previous year[73]. - Total compensation for all directors, supervisors, and senior management at the end of the reporting period amounted to 490.43 million[147]. - The company has a strong focus on continuous product and process innovation, having transitioned several original technologies into industrial applications since 2008[75]. Future Outlook - Future outlook suggests continued growth with a focus on expanding user data and market presence[140]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[143]. - The company plans to enhance its market share in South America and the Asia-Pacific region by promoting PEEK and titanium neurosurgical products[128]. - The company aims to enhance customer engagement through innovative solutions and services[140].

Financial Performance - The company's operating revenue for Q3 2021 was ¥55,289,121.77, representing a year-over-year increase of 26.92%[5] - The net profit attributable to shareholders for Q3 2021 was ¥27,175,982.55, reflecting a 50.52% increase compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥22,599,759.69, showing a significant increase of 99.49% year-over-year[5] - Total revenue for the first three quarters of 2021 reached ¥151,054,585.32, a 33.6% increase compared to ¥113,069,140.66 in the same period of 2020[24] - Net profit for the third quarter of 2021 was ¥61,511,761.41, compared to ¥40,365,225.30 in the same quarter of 2020, representing a 52.3% increase[25] - The net profit attributable to the parent company shareholders for Q3 2021 was ¥61,904,233.22, an increase from ¥41,485,401.32 in Q3 2020, representing a growth of approximately 49.3%[26] - The total comprehensive income attributable to the parent company for Q3 2021 was ¥61,961,081.14, compared to ¥41,215,914.54 in Q3 2020, reflecting a growth of 50.5%[26] Assets and Liabilities - The total assets at the end of Q3 2021 reached ¥541,783,624.50, which is an 85.86% increase compared to the end of the previous year[6] - The total assets of the company as of the end of the third quarter of 2021 amounted to ¥541,783,624.50, significantly higher than ¥291,506,419.87 at the end of the same period in 2020[20] - Current assets totaled ¥347,014,032.66, compared to ¥143,318,132.92 in the previous year, indicating a substantial growth[20] - The company's total liabilities reached ¥59,635,877.98, up from ¥48,458,340.54 in the same period last year[21] - The equity attributable to shareholders increased by 97.94% year-over-year, amounting to ¥484,025,720.10[6] - The equity attributable to shareholders increased to ¥484,025,720.10 from ¥244,534,057.40 year-over-year[21] Earnings and Cash Flow - The basic earnings per share for Q3 2021 was ¥0.47, a 14.63% increase compared to the same period last year[6] - The basic and diluted earnings per share for Q3 2021 were both ¥1.24, compared to ¥0.95 in Q3 2020, indicating a year-over-year increase of 30.3%[27] - Cash flow from operating activities for the first three quarters of 2021 was ¥68,132,297.09, up from ¥38,624,149.10 in the same period of 2020, reflecting a growth of 76.4%[27] - Total cash inflow from operating activities was ¥188,256,785.37, compared to ¥137,841,460.37 in the previous year, marking an increase of 36.5%[27] - The net cash flow from financing activities for Q3 2021 was ¥183,738,361.81, a significant improvement from a net outflow of ¥3,919,836.68 in Q3 2020[28] Research and Development - Research and development expenses totaled ¥2,473,667.20 for Q3 2021, which is a decrease of 19.89% compared to the same period last year[6] - The proportion of R&D expenses to operating revenue was 4.47%, down by 2.62 percentage points year-over-year[6] - Research and development expenses for the third quarter of 2021 were ¥8,228,680.85, slightly down from ¥8,301,936.76 in the previous year[25] - The important research product, 3D printed PEEK craniofacial system, is undergoing clinical trials in five hospitals, with smooth progress in its development registration[16] Production and Operations - The new factory project for the production and research of three types of implantable medical devices is under orderly construction, with the main production and office areas completed[15] - The company has obtained the medical device production license for the new factory, which is expected to enhance production capacity and efficiency[15] - The company plans to complete the relocation to the new factory and related license changes by the end of the year[15] Revenue Breakdown - The company achieved a main business revenue of 146.91 million RMB, a year-on-year increase of 35.07%, and a net profit attributable to shareholders of 61.90 million RMB, up 49.22% year-on-year[15] - Revenue from PEEK material repair products reached 58.21 million RMB, a year-on-year growth of 70.58%[15] - The PEEK material skull fixation products generated revenue of 30.15 million RMB, reflecting a 23.80% increase compared to the same period last year[15] - The revenue from titanium skull repair products was 13.50 million RMB, showing a year-on-year growth of 16.84%[15] - The revenue from titanium skull fixation products was 38.46 million RMB, with a year-on-year increase of 5.86%[15] - The revenue from PEEK material sternum fixation system reached 3.19 million RMB, a significant increase of 1560.52% year-on-year[15]

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, achieving a total of RMB 500 million, representing a 25% year-over-year growth[1]. - The company's operating revenue for the first half of 2021 was ¥95,765,463.55, representing a year-on-year increase of 37.77% compared to ¥69,508,601.75 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2021 was ¥34,728,250.67, an increase of 48.22% from ¥23,430,603.89 in the previous year[19]. - The net cash flow from operating activities increased by 62.03% to ¥30,612,806.46, up from ¥18,892,747.28 in the same period last year[20]. - The total assets at the end of the reporting period were ¥542,225,029.41, reflecting an 86.01% increase from ¥291,506,419.87 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 86.84% to ¥456,896,735.67 from ¥244,534,057.40 at the end of the previous year[20]. - Basic earnings per share for the first half of 2021 were ¥0.76, a 40.74% increase from ¥0.54 in the same period last year[21]. - The company achieved a weighted average return on equity of 13.26%, an increase of 1.8 percentage points from 11.46% in the previous year[21]. Market Expansion and Product Development - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30% based on current market trends and demand[1]. - New product development includes the launch of a cutting-edge titanium cranial repair product, expected to contribute an additional RMB 100 million in revenue by the end of the year[1]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish partnerships with local distributors[1]. - A strategic acquisition of a smaller competitor is in progress, which is anticipated to enhance the company's product offerings and market share by 10%[1]. - The company aims to expand its product lines in neurosurgery and thoracic surgery while also venturing into oral and spinal fields[27]. - The company is actively developing multiple research projects, including artificial dura mater and disposable neurosurgical drainage devices, to expand its product line[52]. Research and Development - The company has invested RMB 50 million in R&D for innovative medical technologies, aiming to improve operational efficiency and product quality[1]. - The research and development expenditure as a percentage of operating revenue was 6.01%, down 1.49 percentage points from 7.50% in the previous year[21]. - The company achieved a total R&D investment of ¥5,755,013.65, representing a 10.38% increase compared to the previous period's ¥5,213,960.27[43]. - The company developed a personalized skull defect repair technology using PEEK materials, enhancing customization and aesthetic outcomes compared to traditional titanium materials[40]. - The company has implemented a 3D printing technology for producing PEEK plates, which improves material efficiency and processing accuracy[40]. Risks and Challenges - No significant risks were identified during the reporting period that could impact the company's operations or financial performance[1]. - The company faces risks related to the high technical difficulty and lengthy development cycles of Class III medical devices, which could impact long-term competitiveness if registration fails[60]. - There is a risk of supply chain disruption for critical raw materials like PEEK, which could affect production and sales if suppliers cannot meet quality standards or increase prices[61]. - The penetration rate of PEEK cranial repair products is currently low in the domestic market, and any obstacles to market adoption could negatively impact sales growth[61]. - Integration risks exist following the acquisition of BIOPLATE, as effective management is crucial for maintaining operational performance and profitability[62]. Financial Position and Assets - Cash and cash equivalents at the end of the period reached ¥303,048,222.23, accounting for 55.89% of total assets, a significant increase of 226.55% compared to the previous year[75]. - The total liabilities of the company as of June 30, 2021, were RMB 87,117,450.44, compared to RMB 48,458,340.54 at the end of 2020, reflecting an increase of around 80%[178]. - The equity attributable to the parent company reached RMB 456,896,735.67, up from RMB 244,534,057.40, which is an increase of approximately 87%[178]. - The company's inventory as of June 30, 2021, was RMB 40,790,599.14, compared to RMB 36,365,569.61 at the end of 2020, showing an increase of about 12%[176]. Shareholding and Corporate Governance - The company has made commitments regarding shareholding restrictions for key personnel, including Hu Liren, who is restricted from transferring shares for 36 months post-IPO[94]. - The company will ensure compliance with regulations regarding shareholding and changes in shareholding for directors and senior management[106]. - The company has established a profit distribution policy in accordance with relevant laws and regulations, which will be strictly followed post-listing[130]. - The controlling shareholder commits to increase stock holdings according to the stock price stabilization plan after conditions are met[123]. Compliance and Environmental Responsibility - The company meets the emission standards for industrial waste gas and has proper disposal measures for hazardous waste[90]. - There have been no administrative penalties related to environmental issues during the reporting period[91]. - The company has not disclosed any additional environmental information or measures taken to reduce carbon emissions[92].